Paritaprevir
Spécifications
1216941-48-8Numéro CAS
(1S,4R,6S,7Z,14S,18R)-N-cyclopropylsulfonyl-14-[(5-methylpyrazine-2-carbonyl)amino]-2,15-dioxo-18-phenanthridin-6-yloxy-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-ene-4-carboxamideNom IUPAC
C40H43N7O7SFormule chimique
765.9 g/molMasse molaire
Paritaprevir; 1216941-48-8; Veruprevir; ABT-450; Veruprevir anhydrous; ABT450; OU2YM37K86; ABT 450; (2R,6S,12Z,13aS,14aR,16aS)-N-(Cyclopropylsulfonyl)-6-(5-methylpyrazin-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16atetradecahydrocyclopropa(E)pyrrolo(1,2-a)(1,4)diazacyclopentadecine-14a(5H)-carboxamide; DTXSID601027922; VIEKIRAX COMPONENT PARITAPREVIR; (1S,4R,6S,7Z,14S,18R)-N-cyclopropylsulfonyl-14-[(5-methylpyrazine-2-carbonyl)amino]-2,15-dioxo-18-phenanthridin-6-yloxy-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-ene-4-carboxamide; CHEBI:85188; empty; paritaprevirum; (1S,4R,6S,7Z,14S,18R)-N-cyclopropylsulfonyl-14-((5-methylpyrazine-2-carbonyl)amino)-2,15-dioxo-18-phenanthridin-6-yloxy-3,16-diazatricyclo(14.3.0.04,6)nonadec-7-ene-4-carboxamide; RefChem:170090; DTXCID501513483; (2R,6S,12Z,13aS,14aR,16aS)-N-(Cyclopropylsulfonyl)-6-(((5-methyl-2-pyrazinyl)carbonyl)amino)-5,16-dioxo-2-(6-phenanthridinyloxy)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa(e)pyrrolo (1,2-a)(1,4)diazacyclopentadecine-14a(5H)-carboxamide; 1221573-85-8; (2R,6S,13aS,14aR,16aS,Z)-N-(cyclopropylsulfonyl)-6-(5-methylpyrazine-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a-carboxamide; Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide, N-(cyclopropylsulfonyl)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-6-[[(5-methyl-2-pyrazinyl)carbonyl]amino]-5,16-dioxo-2-(6-phenanthridinyloxy)-, (2R,6S,12Z,13aS,14aR,16aS)-; Paritaprevir(ABT-450); Paritaprevir (ABT-450); (2R,6S,13aS,14aR,16aS,Z)-N-(Cyclopropylsulfonyl)-6-(5-methylpyrazine-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide; Veruprevir [INN]; Paritaprevir [USAN]; Paritaprevir [USAN:INN]; UNII-OU2YM37K86; PARITAPREVIR [MI]; PARITAPREVIR [INN]; PARITAPREVIR [VANDF]; veruprevir (deprecated INN); PARITAPREVIR [WHO-DD]; orb1304404; orb1305953; SCHEMBL3069964; CHEMBL3391662; SCHEMBL29359149; C40H43N7O7S; GTPL11273; GLXC-10645; PARITAPREVIR [ORANGE BOOK]; (2R,6S,12Z,13aR,14aR,16aS)-N-(cyclopropanesulfonyl)-6-[(5-methylpyrazine-2-carbonyl)amino]-5,16-dioxo-2-[(phenanthridin-6-yl)oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide; EX-A2278; Paritaprevir(Veruprevir ABT-450)?; EBC-27456; AKOS025396424; CCG-270449; CS-5051; DB09297; NCGC00509859-02; AC-33061; AP178043; AS-75348; DA-66492; HY-12594; T22394; EN300-21959124; BRD-K89920762-001-01-4; (1S,4R,6S,7Z,14S,18R)-N-(cyclopropanesulfonyl)-14-(5-methylpyrazine-2-amido)-2,15-dioxo-18-(phenanthridin-6-yloxy)-3,16-diazatricyclo[14.3.0.0,4,6]nonadec-7-ene-4-carboxamide; (1S,4R,6S,7Z,14S,18R)-N-(cyclopropanesulfonyl)-14-(5-methylpyrazine-2-amido)-2,15-dioxo-18-(phenanthridin-6-yloxy)-3,16-diazatricyclo[14.3.0.0?,?]nonadec-7-ene-4-carboxamide; (2R,6S,12Z,13aS,14aR,16aS)-N-(Cyclopropylsulfonyl)-6-{[(5-methylpyrazin-2-yl)carbonyl]amino}-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[E]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamideSynonymes